Moneycontrol PRO

you are here: HomeNewsBusinessCompaniesRealisations from insulin biosimilar to start from FY17: Biocon

SHOW NAMES

Trending Topics

Sensex Live RPP Infra Projects Shares Zydus Lifesciences Shares Amanta Healthcare IPO Allotment LIVE GST on Health Insurance

business

Realisations from insulin biosimilar to start from FY17: Biocon

Getting approval to sell the biosimilar drug Glargine in Japan will open doors for the company, feels Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon.

first published: Mar 28, 2016 04:04 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347